Darlene Deptula-Hicks - 09 Jun 2026 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)

Reporting relationship: Director
Issuer ticker: ALDX
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 16:18:19 UTC
Prior SEC filing: 09 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Darlene Deptula-Hicks

Key filing fact

Darlene Deptula-Hicks filed Form 4 for Aldeyra Therapeutics, Inc. (ALDX) on 11 Jun 2026.

Key facts

This page summarizes Darlene Deptula-Hicks's Form 4 filing for Aldeyra Therapeutics, Inc. (ALDX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 11 Jun 2026, 16:18.

Change

Previous filing in this sequence was filed on 09 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001089409 Primary reporting owner

DEPTULA-HICKS DARLENE M

Relationship: Director
Address: C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON
Signature: /s/ Darlene Deptula-Hicks
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALDX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +84,557
Change %
Price: $0.000000^*
Shares after: 84,557
Date: 09 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 84,557
Exercise price: $1.72
Footnotes: F1

ALDX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +9,756
Change %
Price: $0.000000^*
Shares after: 9,756
Date: 09 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,756
Exercise price: $1.72
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock option is exercisable in equal annual installments over three years of continuous service to the Issuer after June 9, 2026.

Footnote F2

Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.